| Product Unit Size | Cost | Quantity | Stock |
|---|
Decernotinib is a potent and selective inhibitor of JAK3. It exhibits anti-inflammatory effects in rat models of rheumatoid arthritis, while avoiding hematopoiesis, a problem with current non-selective JAK inhibitors. Methotrexate treatment is also improved when used in combination with decernotinib.
| Cas No. | 944842-54-0 |
|---|---|
| Purity | ≥99% |
| Formula | C18H19F3N6O |
| Formula Wt. | 392.39 |
| IUPAC Name | N2-[2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]-N-(2,2,2-trifluoroethyl)-D-isovalinamide |
| Synonym | VX-509, VRT-831509, Adelitinib |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Farmer L., Ledeboer M., et al. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. J Med Chem. 58(18):7195-216 (2015). PMID: 26230873.
Elwood F., Witter D., et al. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. 361(2):229-44 (2017). PMID:28193636.
Genovese M., van Vollenhoven R., et al. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 68(1):46-55 (2016). PMID: 26473751.